Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications.

MedComm (2020) · 2026 · PMC13092922 · PMID 42017056

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.060so close (0.05 < p ≤ 0.1)

In the intention‐to‐treat population, median OS was 10.8 months (95% CI: 7.7–17.6) in the ivosidenib arm versus 9.7 months (95% CI: 4.8–12.1) in the placebo arm, which did not reach statistical significance (HR 0.69, 95% CI: 0.44–1.10, one‐sided p = 0.060).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.